Follow Us On:
Are You Attending?
J.P. Morgan (JPM) 2024 42nd Annual Healthcare Conference in San Francisco
Optimize your sell-side and buy-side deal-making before or after JPM. Let Vault’s team help you with your next steps.
Why Partner With Vault?
Sell-side or buy-side, we know what is important and how to express it.
Sell-Side Business Impact Study
Mid-size Pharma
Situation
A client had two CRL letters to show for two submissions of their metabolic disease asset. The issues involved phase 3 safety & efficacy data critical for approval and subsequent licensing. As product was to be discussed at FDA’s EMDAC prior to approval, Vault Bio was hired to conduct full diligence on NDA submission quality and ability to be approved.
Approach
Evaluated entire data package and recommended shift in strategy to enhance benefit/risk profile.
Implemented strategy and assisted in developing the EMDAC Briefing Document and helping guide FDA meeting prep.
Impact
EMDAC strongly voted to recommend product approval in T1D (13-1) and in T2D (14-0) based on Briefing Document and meeting data presentation, ultimately enabling a commercial licensing deal.
Buy-Side Business Impact Study
Top 10 Pharma
Situation
A client had two CRL letters to show for two submissions of their metabolic disease asset. The issues involved phase 3 safety & efficacy data critical for approval and subsequent licensing. As product was to be discussed at FDA’s EMDAC prior to approval, Vault Bio was hired to conduct full diligence on NDA submission quality and ability to be approved.
Approach
Vault performed rapid asset analysis based on differentiating drug attributes and competitive considerations. Several critical risks and potential upsides were identified. Vault built an analytical case to compress the downside and shift significant potential value from the seller to the buyer. Partnered with the internal BD leads to develop negotiation and deal-terms highly favorable to the client.
Impact
Based on the deal, the client was a finalist for ‘Licensing Deal of the Year’ for the innovative deal structure. The product was licensed, launched, and performed to the downside case per the identified risk. Because of the risk mitigation and deal-structure, the losses were negligible.
Our Team has Walked in Your Shoes
We have helped small pharma, biotech, medical device and digital therapeutics startups through global enterprises design and develop highly differentiated products, build and sustain better brands, and forge stronger businesses.
Powerful Ideas Powerfully Communicated
Vault’s Ability To Analyze The Science And Bridge To The Business Strategically, Verbally, And Visually Communicates The True, And Often Hidden Value Of Your Life Science Products, Brands, And Businesses.
Financial Modeling & Value Quantification
- Forecasting
- eNPV
- Competitive analysis
- Value expression
Story Telling, Evolution, Messaging & Narrative
- Differentiation
- Market opportunity
- Competitive considerations
- The value
Highly Effective Presentation of The Story & Value
- Not just words on slides
- We craft data driven presentations that align with investor needs
- We design, develop, and evolve your content and visual assets
Meet CEO Joe Young & SVP Joachim Osther
Vault Leadership from J.P. Morgan (JPM) 2024 42nd Annual Healthcare Conference
